Veraxa Biotech AG - Post de-SPAC

VRXA · VRXAW · Pharmaceutical Preparations

Latest available SEC filing: 4 ·

Latest disclosures

  • Gruninger Marc: Form 4

    Insider disclosure · Filed · Report period 27 Oct 2026

  • Form 4

    SEC filing · Filed

  • Form 4

    SEC filing · Filed

  • Form 3

    SEC filing · Filed

  • Form 4

    SEC filing · Filed

  • Form 4

    SEC filing · Filed

  • Form 3

    SEC filing · Filed

All company filings

Institutional holders by security

Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.

  • VRXA · H9130A103 - Ordinary Shares, par value CHF 100/11,325 per share
  • VRXAW · H9130A111 - Ordinary Shares, par value CHF 100/11325 per share
Company details and SEC sources

CIK 0002079109 · SEC filing index. Filing dates describe disclosures, not live market data.

At a glance Names, identifiers, and filing context for this profile. 2 identity fields
Business address
Talacker 35, Zurich, 8001
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
Switzerland
Fiscal year end
31 December
Former names on EDGAR
Veraxa Biotech Holding AG (to 13 Aug 2026)
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .